Efficacy of Pioglitazone Compared to Glyburide in Treating Subjects With Type 2 Diabetes Mellitus and Mild Cardiac Disease

Phase 3 Completed 300 enrolled Takeda Takeda Pharmaceuticals North America, Inc. · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the cardiovascular effects of pioglitazone, once daily (QD), versus glyburide when administered to patients with type 2 diabetes mellitus and mild cardiac disease.

Timeline

Start: 2001-03
Primary completion: 2003-01
Completion: 2003-01

Publications

Results Giles TD, Elkayam U, Bhattacharya M, Perez A, Miller AB. Comparison of pioglitazone vs glyburide in early heart failure: insights from a randomized controlled study of patients with type 2 diabetes and mild cardiac disease. Congest Heart Fail. 2010 May-Jun;16(3):111-7. doi: 10.1111/j.1751-7133.2010.00154.x.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Glyburide	Small molecule	2.5 mg	Oral
Comparator	Glyburide	Small molecule	5 mg	Oral
Comparator	Glyburide	Small molecule	10 mg	Oral
Comparator	Glyburide	Small molecule	15 mg	Oral
Subject	Pioglitazone	Small molecule	15 mg	Oral
Subject	Pioglitazone	Small molecule	30 mg	Oral
Subject	Pioglitazone	Small molecule	45 mg	Oral

Efficacy of Pioglitazone Compared to Glyburide in Treating Subjects With Type 2 Diabetes Mellitus and Mild Cardiac Disease

Summary

Timeline

Publications

Drugs

Indications